HC Wainwright Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $50.00

Dyne Therapeutics (NASDAQ:DYN) had its price target decreased by HC Wainwright from $60.00 to $50.00 in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.76) EPS and Q3 2026 earnings at ($0.76) EPS.

DYN has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Robert W. Baird set a $30.00 target price on shares of Dyne Therapeutics in a research note on Monday, December 8th. Royal Bank Of Canada increased their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 price objective on shares of Dyne Therapeutics in a report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.00.

Dyne Therapeutics Stock Down 0.2%

NASDAQ DYN opened at $15.20 on Tuesday. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $25.00. The stock has a market cap of $2.51 billion, a PE ratio of -4.29 and a beta of 1.34. The firm has a 50-day simple moving average of $17.15 and a 200 day simple moving average of $17.03. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.47 and a current ratio of 22.25.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of DYN. AQR Capital Management LLC acquired a new position in shares of Dyne Therapeutics in the 1st quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after purchasing an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Dyne Therapeutics during the first quarter worth $157,000. Finally, CWM LLC increased its stake in shares of Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after buying an additional 1,900 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $50 price target while publishing quarter-by-quarter EPS forecasts that are in line with management’s cadence — this is supportive for longer‑term sentiment. HC Wainwright reiterates Buy, $50 PT
• Positive Sentiment: Lifesci Capital nudged up its Q1 and Q3 2026 EPS forecasts slightly (Q1: from -$0.77 to -$0.76; Q3: from -$0.85 to -$0.83), signaling modestly improved near-term expectations from that shop. Lifesci raises Q1 & Q3 forecasts
• Neutral Sentiment: Reported short interest data for early March is effectively zero/indeterminate (entry shows 0 shares and NaN change), so short-covering or large new shorts are not a current driver based on that release.
• Neutral Sentiment: Several small, offsetting analyst estimate moves from Lifesci Capital (Q2 and Q4 nudged slightly lower while other quarters nudged higher) leave the consensus full‑year loss estimate unchanged at roughly -$3.44, implying no material change to the broad street view. Lifesci mixed estimate revisions
• Negative Sentiment: Investors reacted to the company’s latest quarterly result, which missed EPS expectations (reported -$0.76 vs. consensus -$0.74), prompting an immediate negative move in the stock. Stock down after disappointing earnings
• Negative Sentiment: Lifesci Capital lowered its Q4 2026 EPS forecast slightly (from -$0.85 to -$0.86) and trimmed other quarter forecasts overall, reflecting modest downward revisions to near‑term profitability expectations. Lifesci lowers Q4 forecast

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.